Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof

US12338440B2 · kind B2 · utility

Assignee

• IOMX THERAPEUTICS AG · DE

Inventors

• Antonio Sorrentino · Heidelberg, DE
• Philipp Beckhove · Heidelberg, DE
• Tillmann MICHELS · Heidelberg, DE
• Nisit Khandelwal · Heidelberg, DE
• Michael Boutros · Heidelberg, DE
• Marco Breinig · Bad Rappenau, DE
• Peter Sennhenn · Munich, DE
• Sebastian Meier-Ewert · Martinsried, DE
• Valentina VOLPIN · Regensburg, DE
• Ayse Nur MENEVSE · Regensburg, DE

Key dates

• Filing date: Apr 20, 2018
• Grant date: Jun 24, 2025
• Expiry date: Jan 19, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.